- Home
- DMAC vs ARBE Comparison
DMAC vs ARBE Comparison
Compare DMAC & ARBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- ARBE
- Stock Information
- Founded
- DMAC 2000
- ARBE 2015
- Country
- DMAC United States
- ARBE Israel
- Employees
- DMAC N/A
- ARBE N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- ARBE EDP Services
- Sector
- DMAC Health Care
- ARBE Technology
- Exchange
- DMAC Nasdaq
- ARBE Nasdaq
- Market Cap
- DMAC 260.0M
- ARBE 203.2M
- IPO Year
- DMAC N/A
- ARBE N/A
- Fundamental
- Price
- DMAC $4.45
- ARBE $1.38
- Analyst Decision
- DMAC Strong Buy
- ARBE Buy
- Analyst Count
- DMAC 4
- ARBE 2
- Target Price
- DMAC $10.75
- ARBE $1.75
- AVG Volume (30 Days)
- DMAC 393.5K
- ARBE 1.4M
- Earning Date
- DMAC 08-06-2025
- ARBE 08-07-2025
- Dividend Yield
- DMAC N/A
- ARBE N/A
- EPS Growth
- DMAC N/A
- ARBE N/A
- EPS
- DMAC N/A
- ARBE N/A
- Revenue
- DMAC N/A
- ARBE $671,000.00
- Revenue This Year
- DMAC N/A
- ARBE $285.16
- Revenue Next Year
- DMAC N/A
- ARBE $370.11
- P/E Ratio
- DMAC N/A
- ARBE N/A
- Revenue Growth
- DMAC N/A
- ARBE N/A
- 52 Week Low
- DMAC $3.19
- ARBE $0.85
- 52 Week High
- DMAC $6.82
- ARBE $5.09
- Technical
- Relative Strength Index (RSI)
- DMAC 53.15
- ARBE 37.85
- Support Level
- DMAC $4.81
- ARBE $1.44
- Resistance Level
- DMAC $5.60
- ARBE $1.67
- Average True Range (ATR)
- DMAC 0.49
- ARBE 0.10
- MACD
- DMAC 0.05
- ARBE -0.02
- Stochastic Oscillator
- DMAC 43.21
- ARBE 3.33
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.